Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Congenital Hyperinsulinism

• Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
• Treatment of Post-bariatric Hypoglycaemia
• HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
• Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
• 18F-DOPA II - PET Imaging Optimization
• Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
• An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
• Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
• Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
• Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
• Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
• Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
• Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia
• Pasireotide in Hyperinsulinemic Hypoglycemia
• 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
• CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
• Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
• Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
• A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
• Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
• Sirolimus for the Treatment of Hyperinsulinism
• Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
• 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
• Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia
• Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
• Sandostatine® LP and Hyperinsulinism
• Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
• Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
• Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
• Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism